Inhibikase Therapeutics, Inc. (IKT) Q1 2026 Earnings
IKT·Reported May 12, 2026·Before market open
Diluted EPS came in at $-0.10 (+33.3% YoY).
Diluted EPS
$-0.10met estimate
Consensus: $-0.10
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Inhibikase Therapeutics, Inc.'s Q1 2026 earnings report.
Inhibikase Therapeutics, Inc. (IKT) reported Q1 2026 earnings on May 12, 2026 before market open.
Inhibikase Therapeutics, Inc. reported diluted EPS of $-0.10 for Q1 2026.
EPS beat the consensus estimate of $-0.10 by $0.00.
Compared to the same quarter a year prior, diluted EPS grew 33.3% from $-0.15.
You can read the 8-K earnings release (0001193125-26-219610) and the 10-Q periodic report (0001193125-26-219641) directly on SEC EDGAR. The filing index links above go to sec.gov.